Zinc and COVID-19: basis of current clinical trials
Abstract Coronavirus disease-2019 (COVID-19) pandemic continues to threaten patients,
societies, and economic and healthcare systems around the world. Like many other …
societies, and economic and healthcare systems around the world. Like many other …
SARS-CoV-2 and the nervous system: from clinical features to molecular mechanisms
M Pennisi, G Lanza, L Falzone, F Fisicaro… - International journal of …, 2020 - mdpi.com
Increasing evidence suggests that Severe Acute Respiratory Syndrome-coronavirus-2
(SARS-CoV-2) can also invade the central nervous system (CNS). However, findings …
(SARS-CoV-2) can also invade the central nervous system (CNS). However, findings …
Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial
CP Skipper, KA Pastick, NW Engen… - Annals of internal …, 2020 - acpjournals.org
Background: No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).
Objective: To investigate whether hydroxychloroquine could reduce COVID-19 severity in …
Objective: To investigate whether hydroxychloroquine could reduce COVID-19 severity in …
A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19
DR Boulware, MF Pullen, AS Bangdiwala… - New England journal …, 2020 - Mass Medical Soc
Abstract Background Coronavirus disease 2019 (Covid-19) occurs after exposure to severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the …
SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery
Summary Coronavirus disease 2019 (COVID-19) is the latest respiratory pandemic caused
by severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). Although …
by severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). Although …
Patient characteristics and outcomes of 11 721 patients with coronavirus disease 2019 (COVID-19) hospitalized across the United States
MW Fried, JM Crawford, AR Mospan… - Clinical Infectious …, 2021 - academic.oup.com
Background As coronavirus disease 2019 (COVID-19) disseminates throughout the United
States, a better understanding of the patient characteristics associated with hospitalization …
States, a better understanding of the patient characteristics associated with hospitalization …
A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19
O Mitjà, M Corbacho-Monné, M Ubals… - … England Journal of …, 2021 - Mass Medical Soc
Background Current strategies for preventing severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection are limited to nonpharmacologic interventions …
coronavirus 2 (SARS-CoV-2) infection are limited to nonpharmacologic interventions …
Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo
S Weston, CM Coleman, R Haupt, J Logue… - Journal of …, 2020 - Am Soc Microbiol
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China at the
end of 2019 and has rapidly caused a pandemic, with over 20 million recorded COVID-19 …
end of 2019 and has rapidly caused a pandemic, with over 20 million recorded COVID-19 …
A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment
Many recent studies have investigated the role of either Chloroquine (CQ) or
Hydroxychloroquine (HCQ) alone or in combination with azithromycin (AZM) in the …
Hydroxychloroquine (HCQ) alone or in combination with azithromycin (AZM) in the …
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
Purpose To study the efficacy of lopinavir-ritonavir and hydroxychloroquine in critically ill
patients with coronavirus disease 2019 (COVID-19). Methods Critically ill adults with COVID …
patients with coronavirus disease 2019 (COVID-19). Methods Critically ill adults with COVID …